BerGenBio ASA (BRRGF) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BerGenBio ASA has appointed Olav Hellebø as its new CEO, bringing extensive experience from the pharmaceutical and biotechnology industries to the company. Hellebø’s leadership is expected to drive the development of BerGenBio’s lead candidate, bemcentinib, aimed at treating STK11 mutated non-small cell lung cancer. Investors and stakeholders may find this leadership change promising for the company’s strategic growth and clinical advancement.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.